Blackstone Life Sciences, a private equity segment of The Blackstone Group, completed the $350m investment in Reata Pharmaceuticals, a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases. "This investment aligns with Blackstone Life Sciences’ mission to help advance promising new medicines to patients with high unmet needs. If approved, bardoxolone has the potential to provide for the first time a therapy that improves the quality of life for tens of thousands of patients around the world suffering from Alport syndrome," Nicholas Galakatos, Blackstone Life Sciences Global Head.